Select Language
DRD1
DRD1 Overview
| English Name | Dopamine D1 receptor | Approved Drugs | 10 |
| Drugs in Clinical Trials | 15 | Target Synonym | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Highest Development Stage | Approved | ||
| English Name | Dopamine D1 receptor |
| Target Synonym | D(1A) dopamine receptor，DRD1，Dopamine Receptor D1，Dopamine D1 Receptor，DRD1A，DADR，Receptors， Dopamine D1 |
| Approved Drugs | 10 |
| Drugs in Clinical Trials | 15 |
| Highest Development Stage | Approved |
DRD1 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
- (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
DR1-H52P6 |  Human | HEK293 | Human DRD1 Full Length Protein (VLP) |  |
Total: 1
- 1
DRD1 Background
The dopamine receptor D1 (Drd1) is a member of the D1-like receptor family and is the most abundant dopamine receptor in the central nervous system. The receptor is found in the cortex, striatum and limbic system of the brain and the cardiovascular system.
DRD1 Synonyms
DRD1,Dopamine D1 receptor,D1R; DADR; DRD1A
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Childhood-Onset Fluency Disorder; Gambling; Language Disorders; Lesch-Nyhan Syndrome; Self-Injurious Behavior; Speech Disorders; Stuttering; Tourette Syndrome | Details |
| Olanzapine transdermal patch (Starton Therapeutics) | CMIO-OLANZ; CHEMIO OLANZ; CMIO-OLNZ; STAR-OLZ | Phase 3 Clinical | Starton Therapeutics Inc | Nausea; Vomiting | Details |
| Olanzapine/samidorphan (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Schizophrenia | Details | |
| PF-06412562 | PF-6412562; PF-06412562; PF-2562; CVL-562 | Phase 2 Clinical | Pfizer Inc | Parkinson Disease; Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders | Details |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease; Lewy Body Disease; Parkinson Disease | Details |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | Details | |
| Glovadalen | UCB-0022 | Phase 2 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | Details |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | Details | |
| asenapine schizophrenia (Livzon Pharmaceutical/LTS Lohmann Therapie-Systeme) | Phase 1 Clinical | Lts Lohmann Therapie-Systeme Ag | Schizophrenia | Details | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | Details |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | Details | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Mood Disorders; Opioid-Related Disorders; Pain | Details |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | Details | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | Mainland China | Bipolar I Disorder | Jiangsu Changtai Pharmaceutical Co Ltd | 2003-12-24 | Bipolar Disorder; Bipolar I Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant | Details |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Bipolar Disorder; Schizophrenia | Details | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Japan | Postpartum Hemorrhage | Aska Pharmaceutical Co Ltd | 1971-05-01 | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | Details | ||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Alcoholism; Bipolar and Related Disorders; Bipolar Disorder; Bipolar I Disorder; Psychotic Disorders; Schizophrenia | Details |
| Olanzapine | ALKS-7921; LY-170052; LY-170053; INP-105; BR-5402; QLG-2072; QLG2072 | Approved | Eli Lilly And Company | Zyprexa Zydis, Zyprexa Relprevv, Olansek, Zalasta, Zyprexa, Zyprexa Velotab, Olanzapine ODF, Lanzac, Zypadhera, 再普乐, Midax | EU | Bipolar Disorder; Schizophrenia | null | 1996-09-27 | Anorexia; Anorexia Nervosa; Autistic Disorder; Biliary Tract Neoplasms; Bipolar Disorder; Bipolar I Disorder; Bipolar II Disorder; Borderline Personality Disorder; Cachexia; Carcinoma, Hepatocellular; Chemotherapy-induced nausea and vomiting; Colorectal Neoplasms; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Emergence Delirium; Esophageal Neoplasms; Fasting; Feeding and Eating Disorders; Gambling; Hematopoietic stem cell transplantation (HSCT); Insulin Resistance; Lung Neoplasms; Malaria, Falciparum; Multiple Myeloma; Nausea; Neoplasms; Opioid-Related Disorders; Postoperative Nausea and Vomiting; Schizophrenia; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Substance-Related Disorders; Tinnitus; Vomiting; Weight Loss | Details |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | Details | ||||||
| Olanzapine Oral Soluble Film(Jiangsu Hansoh) | Approved | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Mainland China | Schizophrenia; Bipolar Disorder | Jiangsu Hansoh Pharmaceutical Group Co Ltd | 2020-11-24 | Bipolar Disorder; Schizophrenia | Details | ||
| Olanzapine Oral Soluble Film(Qilu Pharma) | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Bipolar Disorder; Schizophrenia | Qilu Pharmaceutical Co Ltd | 2021-01-19 | Bipolar Disorder; Schizophrenia | Details | ||
| Stepholidine | Approved | Mainland China | Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders; Headache | null | 1995-01-01 | Attention Deficit Disorder with Hyperactivity; Headache; Migraine Disorders; Tourette Syndrome | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8